Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0T4AN
|
||||
| Former ID |
DNC005839
|
||||
| Drug Name |
4-(4-Butoxy-phenyl)-N-hydroxy-4-oxo-butyramide
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [527800] | ||
| Formula |
C14H19NO4
|
||||
| Canonical SMILES |
CCCCOC1=CC=C(C=C1)C(=O)CCC(=O)NO
|
||||
| InChI |
1S/C14H19NO4/c1-2-3-10-19-12-6-4-11(5-7-12)13(16)8-9-14(17)15-18/h4-7,18H,2-3,8-10H2,1H3,(H,15,17)
|
||||
| InChIKey |
SFIUVAFWSBUQJK-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Interstitial collagenase | Target Info | Inhibitor | [527800] | |
| PANTHER Pathway | Alzheimer disease-presenilin pathway | ||||
| Plasminogen activating cascade | |||||
| WikiPathways | TGF beta Signaling Pathway | ||||
| Bladder Cancer | |||||
| Activation of Matrix Metalloproteinases | |||||
| Degradation of collagen | |||||
| Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis | |||||
| Oncostatin M Signaling Pathway | |||||
| Prostate Cancer | |||||
| Integrated Breast Cancer Pathway | |||||
| Integrated Cancer pathway | |||||
| Cell surface interactions at the vascular wall | |||||
| Matrix Metalloproteinases | |||||
| References | |||||